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Abstract
Neutrophil gelatinase-associated lipocalin (NGAL) is a group of proteins with different functions.
NGAL is released by different cell types such as epithelial cell, hepatocytes and renal tubular cells during inflamma-
tion and after cell injury. Expression of NGAL is induced under various pathophysiological conditions such as infec-
tion, cancer, inflammation, kidney injury, cardiovascular disease, burn injury, and intoxication, which has an
important anti-apoptotic and anti-inflammatory role.
Subjects with Down’s syndrome (DS) are affected by many pathological age related conditions such as mental
retardation, Alzheimer’s disease, immune defects and increased susceptibility to infections. The aim of this study is
to evaluate possible use of NGAL as a marker of inflammatory status for allow an early diagnosis of inflammatory
disease such as autoimmune disease in DS patients, that are more susceptible to these pathologies, especially in
elderly subjects.
In this study were recruited 3 groups of DS subjects (children, adults and elderly) and compared them to healthy
control group.
The molecules of interest was determinated by immuno-enzymatic assay (ELISA).
Our results show that NGAL plasmatic level was significantly higher in DS patients compared to healthy controls.
Moreover NGAL levels increase in correlation with the age, and showed a significantly correlation between the
increase with the severity of disease.
DS is characterized by an enhancement of gene production such as GART, SOD-1 and CBS that encode specific
protein and enzyme involved in hydrogen peroxide and superoxide production, species highly cytotoxic implicated
in inflammation and ageing.
NGAL may have the potential application to ameliorate the toxicity induced by oxidative stress conditions such as
Alzheimer’s disease, thalassemia, cardiovascular disease, burn injury, transplantation, diabetes, and aging.
Introduction
The neutrophil Gelatinase-associated lipocalin (NGAL)
is a member of a large family of lipocalins, a group of
small extracellular proteines with great functional diver-
sity [1]. NGAL is found to be constitutively synthesized
during a narrow window of maturation in the granulo-
cyte precursors in the bone marrow, and is stored in
specific granules of mature neutrophils in complex with
gelatinase [2]. NGAL may also be released by epithelial
cells, renal tubular cells, and hepatocytes during inflam-
mation or injury, and has been found to be expressed in
endothelial cells smooth muscle cells, and macrophages.
The aim of this study is to evaluate possible use of
NGAL as a marker of inflammatory status for allow an
early diagnosis of inflammatory disease such as autoim-
mune disease in DS patients, that are more susceptible
to these pathologies, especially in elderly subjects.
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Subjects with DS suffer many medical conditions,
among which, cardiovascular disease, the most frequent
alteration and the principal cause of mortality; respira-
tory system pathologies, due to the recurrent inflamma-
tory processes; endocrine hypo-functional alterations;
nutritional disturbance; mental retardation and higher
risk to develop neuro-degenerative disease, such as
Alzheimer’s disease; immune defects and increased sus-
ceptibility to infections [3], immune defects of variable
degree regarding both specific and non-specific immu-
nity are present in patients with DS and are responsible
for the increased incidence of infections (above all lung
infections) and autoimmune diseases, in particular of
the thyroid and gastro-enteric system.
Material and methods
Three groups of DS subjects were recruited for this
study: the first group consisted of 23 children (age 2-14
years); the second of 14 adults (age 20-50 years) and the
third of 13 elderly persons (>60 years) these groups
were compared to a group of 20 healthy controls (age 5-
60 years). DS children and adults were living at home
and the elderly were in institutions. All DS patients
were assessed by clinical examination and karyotype
analysis; they had mild and variable degrees of mental
retardation, no other pathological conditions at the time
of the study, and were in good health. The project was
approved by the University of Milan Ethics Committee
and by the Fondazione Antoniana of Bologna, Italy. The
molecule of interest was quantified using immuno-
enzymatic assay (R&D System, Minneapolis,USA).
Results
Our data show (Figure 1) an increase of NGAL serum
level in Down’s syndrome patients respect to healthy
controls. NGAL values in young DS subject show no
significantly difference than controls (75.06+48.73 SD
ng/mL vs 24.89+33.48 SD ng/mL), while there is a sta-
tistical increase in adults (167.51+82.28 SD ng/mL with
p<0.01) and elderly ( 222.13+57.73 SD ng/mL with
p<0.001) DS subjects than controls. Our data also show
that NGAL levels increase in correlation with the age of
patients. Middle age subject had significantly higher
NGAL values than those from DS children (167.51
+82.28 SD ng/mL vs 75.06+48.73 SD ng/mL with
p<0.01), differences were also found between elderly
subjects and DS children (222.13+57.73 SD ng/mL vs
75.06+48.73 SD ng/mL with p<0.001).
The results showed an increase of the levels of this
molecule in our patients respect to a group of healthy
controls. Beside we also observed an NGAL age-related
increase in Down’s syndrome subjects.
Discussion
NGAL is thought to mediate inflammatory responses by
sequestering neutrophil chemoattractans, particularly N-
formylated tripeptides and possibly leukotriene B4, and
platelet-activating factor.
In literature NGAL has been studied in association
with several pathologies, such as, inflammations, auto-
immune diseases, cardiovascular and renal injury and
also in some cancers, showed a significantly correlation
between the increase of NGAL and the course and the
severity of the diseases.
Down’s syndrome is characterized by the onset of dif-
ferent clinical conditions, such as mental retardation,
endocrine and cardiovascular alterations, immune-
defects with possible development of autoimmune dis-
eases, in particular thyroid and gastro-enteric. After the
genetic mapping of chromosome 21 has been possible
to characterize a long list of genes that encode specific
proteins, in particular, genes GART, SOD-1, CBS and
the APP which are present in the corresponding region
22 of the long arm of chromosome 21. Genes GART,
SOD-1, CBS and APP encode specific proteins and
enzymatic activity, respectively involved in the biosynth-
esis of purine, production of hydrogen peroxide (H2O2)
in the metabolism of sulfur amino acids methionine and
cysteine. Increased expression of the GART gene may
lead to increased production of superoxide, reactive oxy-
gen species highly cytotoxic.
Oxidative stress has been implicated in several harm-
ful conditions such as Alzheimer’s disease, cardiovascu-
lar disease, transplantion, burn injury, inflammation,
diabetes and aging [4]. NGAL could act as a cytoprotec-
tive factor against H2O2 toxicity, which is considered to
be the classical inducer of oxidative stress caused by
ROS generation [5].
For these reasons we wanted to associate NGAL, pos-
sible marker of inflammations, with the Down’s syn-
drome which often presents an inflammatory status.
Moreover this study allowed to identify a progressive
increase in relation with aging.
Figure 1 Data show NGAL levels in children, adults and elderly,
expressed as mean + SD (ng/mL).
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In conclusion our pilot study showed that NGAL may
have potential application to ameliorate the toxicity
induced by oxidative stress and pathological conditions.
If present results will be confirmed in a larger sample of
DS subjects, NGAL might be used as a marker of
inflammation and considered a protective factor against
early senescence in subjects with Down’s syndrome.
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